Protein Kinase Cα, but Not PKCβ or PKCγ, Regulates Contractility and Heart Failure Susceptibility
- 17 July 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 105 (2), 194-200
- https://doi.org/10.1161/circresaha.109.195313
Abstract
Protein kinase (PK)Cα, PKCβ, and PKCγ comprise the conventional PKC isoform subfamily, which is thought to regulate cardiac disease responsiveness. Indeed, mice lacking the gene for PKCα show enhanced cardiac contractility and reduced susceptibility to heart failure. Recent data also suggest that inhibition of conventional PKC isoforms with Ro-32-0432 or Ro-31-8220 enhances heart function and antagonizes failure, although the isoform responsible for these effects is unknown. Here, we investigated mice lacking PKCα, PKCβ, and PKCγ for effects on cardiac contractility and heart failure susceptibility. PKCα−/− mice, but not PKCβγ−/− mice, showed increased cardiac contractility, myocyte cellular contractility, Ca2+ transients, and sarcoplasmic reticulum Ca2+ load. PKCα−/− mice were less susceptible to heart failure following long-term pressure-overload stimulation or 4 weeks after myocardial infarction injury, whereas PKCβγ−/− mice showed more severe failure. Infusion of ruboxistaurin (LY333531), an orally available PKCα/β/γ inhibitor, increased cardiac contractility in wild-type and PKCβγ−/− mice, but not in PKCα−/− mice. More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment. Ruboxistaurin was also administered to PKCβγ−/− mice subjected to pressure overload, resulting in less death and heart failure, implicating PKCα as the primary target of this drug in mitigating heart disease. As an aside, PKCαβγ triple-null mice showed no defect in cardiac hypertrophy following pressure-overload stimulation. In conclusion, PKCα functions distinctly from PKCβ and PKCγ in regulating cardiac contractility and heart failure, and broad-acting PKC inhibitors such as ruboxistaurin could represent a novel therapeutic approach in treating human heart failure.Keywords
This publication has 41 references indexed in Scilit:
- Structural Basis of Protein Kinase C Isoform FunctionPhysiological Reviews, 2008
- Inducible and myocyte-specific inhibition of PKCα enhances cardiac contractility and protects against infarction-induced heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Adenovirus-delivered short hairpin RNA targeting PKCα improves contractile function in reconstituted heart tissueJournal of Molecular and Cellular Cardiology, 2007
- Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failureJCI Insight, 2007
- Pharmacological- and Gene Therapy-Based Inhibition of Protein Kinase Cα/β Enhances Cardiac Contractility and Attenuates Heart FailureCirculation, 2006
- Interactions of LY333531 and Other Bisindolyl Maleimide Inhibitors with PDK1Structure, 2004
- Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac HypertrophyCirculation Research, 2004
- Phospholamban: a crucial regulator of cardiac contractilityNature Reviews Molecular Cell Biology, 2003
- Immunodeficiency in Protein Kinase Cβ-Deficient MiceScience, 1996
- (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase CβJournal of Medicinal Chemistry, 1996